8 completed, 1 withdrawn. 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 8, Withdrawn 1 |
| Phase 2 | 3 | Completed 3 |
Follow Rigosertib: new trials by email Literature Review of Rigosertib trials Research Report on Rigosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment Rigosertib, Nivolumab - Non-small Cell Lung Cancer, Adenocarcinoma | Phase 1 / Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 25 | 2020-06-29 | 2024-05-09 |
| Three Dosing Schedules of Oral Rigosertib in MDS Patients rigosertib - Myelodysplastic Syndrome | Phase 1 | Withdrawn | Traws Pharma, Inc. | 2014-05-01 | 2020-07-01 | |
| Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers rigosertib - Healthy | Phase 1 | Completed | Traws Pharma, Inc. | 6 | 2014-01-01 | 2017-06-23 |
| Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors rigosertib - Solid Tumor | Phase 1 | Completed | Traws Pharma, Inc. | 68 | 2010-07-01 | 2017-06-23 |
| Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) rigosertib - Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Traws Pharma, Inc. | 30 | 2010-07-01 | 2017-06-26 |
| Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome ON 01910.Na - Myelodysplastic Syndrome | Phase 1 | Completed | Traws Pharma, Inc. | 36 | 2009-12-01 | 2017-06-23 |
| Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML ON 01910.Na - Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Traws Pharma, Inc. | 36 | 2009-01-01 | 2017-06-26 |
| Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer rigosertib sodium - Advanced Cancer, Solid Tumors | Phase 1 | Completed | Traws Pharma, Inc. | 29 | 2006-08-01 | 2017-06-23 |
| Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer rigosertib sodium - Solid Tumors, Advanced Cancer | Phase 1 | Completed | Traws Pharma, Inc. | 42 | 2006-06-01 | 2017-06-23 |
Myelodysplastic Syndromes (3) · Leukemia, Myeloid, Acute (2) · Neoplasms (2) · Adenocarcinoma (1) · Anemia, Refractory (1) · Carcinoma, Non-Small-Cell Lung (1) · Cytopenia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Myeloproliferative Disorders (1) · Neoplasm Metastasis (1) · Polycythemia Vera (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1) · Thrombocythemia, Essential (1)
Traws Pharma, Inc. (8) · Icahn School of Medicine at Mount Sinai (1)
United States (9)
Azra Raza, MD (2) · Antonio Jimeno, MD, PhD (1) · Francois Wilhelm, MD, PhD (1) · Jorge Cortes, MD (1) · Mark Heaney, MD (1) · Rajwanth Veluswamy, MD, MSCR (1) · Rami Komrokji, MD (1) · Sridhar Mani, MD (1) · Takao Ohnuma, MD (1)